A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis |
| |
Authors: | Hamma-Kourbali Yamina Di Benedetto Mélanie Ledoux Dominique Oudar Olivier Leroux Yves Lecouvey Marc Kraemer Michel |
| |
Institution: | Laboratoire d'Oncologie Cellulaire et Moléculaire, UPRES 2360, Université Paris 13, UFR SMBH, Bobigny, France. |
| |
Abstract: | Bisphosphonates (BP) are powerful inhibitors of bone resorption and are widely used in the treatment of patients with metastasis-induced osteolysis. In the present study, we show that a novel non-nitrogen-containing BP (BP7033) that exhibits antitumor activity is a potent inhibitor of both in vivo and in vitro angiogenesis. When administered to mice, BP7033 inhibited tumoral angiogenesis (65% at 0.06mg/injection) as well as tumor growth (65% at 0.006mg/injection) in a tumor model of A431 cells xenografted in nude mice, with no sign of toxicity. Additionally, in vivo angiogenesis induced by vascular endothelial growth factor-containing Matrigel implants was reduced by 90% in the presence of BP7033 (0.6mg/plug). In vitro, BP7033 inhibited proliferation of human umbilical vein endothelial cells (HUVEC) (IC(50) value 3x10(-4) M) and completely prevented the formation of capillary-like tubules by HUVEC in Matrigel. Moreover, treatment of A431 cells by BP7033 induced an inhibition of Ras processing and a decrease in the secretion of both vascular endothelial growth factor and matrix metalloproteinase-2, two well-known stimulators of the proliferation and migration of endothelial cells. These findings indicate that this new BP compound has marked antiangiogenic properties and thus represents a promising candidate for treatment of malignant diseases with an angiogenic component. |
| |
Keywords: | Bisphosphonate Angiogenesis Endothelial cells MMP-2 VEGF |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|